Previous Study: BCIRG 101
Next Study: BCIRG 103

Studies & Results


Open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as therapy for advanced breast cancer in women with tumors over-expressing the HER2-neu proto-oncogene

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at